|
CH503559A
(de)
|
1969-02-26 |
1971-02-28 |
Arx Paul Von |
Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes
|
|
GB9119920D0
(en)
|
1991-09-18 |
1991-10-30 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
CA2242425C
(en)
|
1996-02-13 |
2006-07-18 |
Zeneca Limited |
Quinazoline derivatives as vegf inhibitors
|
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
|
GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
|
GB9900752D0
(en)
|
1999-01-15 |
1999-03-03 |
Angiogene Pharm Ltd |
Benzimidazole vascular damaging agents
|
|
EE05345B1
(et)
|
1999-02-10 |
2010-10-15 |
Astrazeneca Ab |
Kinasoliini derivaadid angiogeneesi inhibiitoritena
|
|
BR0111230A
(pt)
|
2000-05-31 |
2003-06-10 |
Astrazeneca Ab |
Composto, e, uso e processo para a preparação do mesmo
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
EE200300015A
(et)
|
2000-07-07 |
2004-10-15 |
Angiogene Pharmaceuticals Limited |
Kolhinooli derivaadid kui angiogeneesi inhibiitorid
|
|
KR20030014425A
(ko)
|
2000-07-07 |
2003-02-17 |
앤지오젠 파마슈티칼스 리미티드 |
혈관 손상제인 콜치놀 유도체
|
|
AU2002305236A1
(en)
|
2001-04-24 |
2002-11-05 |
Epigenesis Pharmaceuticals, Inc. |
Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
|
|
SE0102808D0
(sv)
|
2001-08-22 |
2001-08-22 |
Astrazeneca Ab |
New compounds
|
|
JP2004002826A
(ja)
|
2002-04-24 |
2004-01-08 |
Sankyo Co Ltd |
高分子イミダゾピリジン誘導体
|
|
BRPI0515897A
(pt)
|
2004-09-24 |
2008-08-12 |
Astrazeneca Ab |
composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
|
|
JP5198256B2
(ja)
|
2005-05-04 |
2013-05-15 |
エボテク エージー |
縮合複素環式化合物、並びにそれらの組成物及び使用
|
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
|
US20090099195A1
(en)
|
2007-05-08 |
2009-04-16 |
Astrazeneca Ab |
Therapeutic Compounds 570
|
|
US20110237578A1
(en)
|
2008-09-18 |
2011-09-29 |
Zhi-Liang Wei |
Amide compounds, compositions and uses thereof
|
|
ES2442797T3
(es)
|
2009-11-18 |
2014-02-13 |
Neomed Institute |
Compuestos de benzoimidazol y sus utilizaciones
|
|
WO2012158117A1
(en)
|
2011-05-17 |
2012-11-22 |
Astrazeneca Ab |
Combination therapies for treating pain
|
|
WO2013002584A2
(ko)
|
2011-06-28 |
2013-01-03 |
주식회사 비보존 |
다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
|
|
KR102120513B1
(ko)
|
2013-01-31 |
2020-06-08 |
네오메드 인스티튜트 |
이미다조피리딘 화합물 및 이의 용도
|
|
BR112016003157B1
(pt)
|
2013-08-15 |
2021-07-13 |
Volvo Truck Corporation |
Método e disposição para balanceamento de um sistema de armazenamento de energia
|
|
PE20160431A1
(es)
|
2013-08-23 |
2016-06-02 |
Afferent Pharmaceuticals Inc |
Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
|
|
CU24411B1
(es)
|
2014-12-09 |
2019-05-03 |
Bayer Ag |
Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
|
|
CA2998742C
(en)
|
2015-09-29 |
2023-08-29 |
Anthony P. FORD |
Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
|
|
US9907795B2
(en)
*
|
2016-01-08 |
2018-03-06 |
Nerre Therapeutics Limited |
Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
|
|
US10822311B2
(en)
|
2016-03-14 |
2020-11-03 |
Afferent Pharmaceuticals, Inc. |
Pyrimidines and variants thereof, and uses therefor
|
|
CN109462996A
(zh)
|
2016-03-17 |
2019-03-12 |
西达-赛奈医疗中心 |
通过rnaset2诊断炎性肠病的方法
|
|
CN109996546B
(zh)
|
2016-09-30 |
2023-06-27 |
阿沙纳生物科学公司 |
P2x3和/或p2x2/3化合物及方法
|
|
US10111883B1
(en)
*
|
2017-09-18 |
2018-10-30 |
Bellus Health Cough Inc. |
Selective P2X3 modulators
|
|
CN108904507A
(zh)
|
2018-02-11 |
2018-11-30 |
赖英杰 |
P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
|
|
DK3880678T3
(da)
*
|
2018-11-13 |
2025-06-10 |
Glaxosmithkline Intellectual Property No 3 Ltd |
Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat
|
|
WO2020112890A1
(en)
|
2018-11-29 |
2020-06-04 |
Cedars-Sinai Medical Center |
Rnaset2 compositions and methods of treatment therewith
|
|
KR102797127B1
(ko)
|
2018-12-29 |
2025-04-21 |
우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 |
헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도
|
|
CA3131312A1
(en)
|
2019-02-25 |
2020-09-03 |
Bellus Health Cough Inc. |
Treatment with p2x3 modulators
|
|
BR112022015818A2
(pt)
|
2020-02-14 |
2022-10-25 |
Bellus Health Cough Inc |
Preparação de um antagonista de p2x3
|
|
JP2023513373A
(ja)
|
2020-02-14 |
2023-03-30 |
べルス・ヘルス・コフ・インコーポレーテッド |
Ｐ２ｘ３修飾薬
|